Not yet recruitingPhase 1NCT07523282

Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases

Studying Diffuse cutaneous systemic sclerosis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Shenzhen MagicRNA Biotechnology Co., Ltd
Principal Investigator
Zhu Chen
The First Affiliated Hospital of University of Science and Technology of China
Intervention
HN2302 Injection(drug)
Enrollment
12 enrolled
Eligibility
18-69 years · All sexes
Timeline
2026 – 2028

Study locations (1)

Collaborators

The First Affiliated Hospital of University of Science and Technology of China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07523282 on ClinicalTrials.gov

Other trials for Diffuse cutaneous systemic sclerosis

Additional recruiting or active studies for the same condition.

See all trials for Diffuse cutaneous systemic sclerosis →

← Back to all trials